Drugs / DCR-PH1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02795325 | May → Oct 2016 | primary hyperoxaluria type 1 | Dicerna Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCR-PH1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02795325 ↗ |
| Route | Intravenous | “IV infusion of DCR-PH1” NCT02795325 ↗ |